Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer
β Scribed by Jackson E. Fowler Jr.; Willet F. Whitmore Jr.
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 445 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Neuroendocrine (NE) differentiation of prostatic adenocarcinomas has received increasing attention in recent years as a result of possible implications on prognosis and therapy. The incidence of NE cells in tumors has been reported from 10% up to 100%. Several studies have shown chromogranin A (CgA)
## Background: Prostate cancer is presently diagnosed by transrectal ultrasound (trus)-guided sextant needle biopsy. while echo texture of the tissue can prompt localization of tumor, it is presently imprecise. from 50-75% of men biopsied, based on an abnormal digital rectal examination (dre) or el
The characteristic sclerotic appearance of bone metastases from prostate cancer is unexplained but could involve excess peritumoural activity of osteoblast mitogens such as the insulin-like growth factors (IGFs). Since prostatic metastases are distinguished by androgen-dependent secretion of prostat